MYC and non-small cell lung carcinoma: In line with this, SFN was found to enhance the therapeutic outcomes of cisplatin in non-small cell lung cancer (NSCLC) models, both in vitro and in vivo, by sensitizing the cells to cisplatin treatment by downregulating the expression of cellular Myc (c-Myc) [104].